Ledger. Australian venture funding, tracked

Buchan Consulting

Haley Price

Coverage

Stories naming Haley Price. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Funding announcement

HATCHTECH RECEIVES FDA SPECIAL PROTOCOL AGREEMENT OF DEOVO PHASE III STUDIES

Hatchtech announced FDA sign-off on its DeOvo Phase 3 trials and two extra patents; its profile names GBS Venture Partners among the company's investors.

GBS Ventures 12 Dec 2013 AustralianSuperBlue Sky Alternative InvestmentsBuchan ConsultingGBS VenturesHatchtechOneVentures Innovation FundQueensland Biotechnology FundUniseedUniversity of Melbourne EndowmentAustralian GovernmentHaley PriceHugh Alsop
Unnamed stage $12.6m

HATCHTECH COMPLETES $12.6M CAPITAL RAISE

Melbourne drug developer Hatchtech raised A$12.6 million, with OneVentures Innovation Fund leading, to advance its head lice treatment toward Phase III trials; board changes brought in Richard Treagus and Hugh Alsop.

GBS Ventures 31 Oct 2013 HatchtechAcruxAustralianSuperBuchan ConsultingGBS VenturesNeuren PharmaceuticalsUniversity of Melbourne EndowmentAustralian GovernmentBlue Sky Alternative InvestmentsOneVentures Innovation FundQueensland Biotechnology FundUniseedUniversity of MelbourneHaley PriceHugh AlsopDr John KurekDr Ross Macdonald

Something wrong? Tell us